Across TCGA pan-cancer cohorts, TSPO Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated TSPO data layer compared with 23 for mass-spec protein and 6 for mass-spec protein.
The strongest signal is observed in kidney chromophobe (KICH), where higher TSPO Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated TSPO expression acts as an unfavorable survival marker.
KICH are the cancer types where TSPO Mutation most reproducibly stratifies survival.